Stage-specific outcomes of patients with Uterine leiomyosarcoma: A comparison of the international federation of gynecology and obstetrics and american joint committee on cancer staging systems
Uterine Cervical Neoplasms
Estimates of stage-specific PFS and OS for uterine LMS were altered substantially when using the AJCC versus FIGO staging system. Adjuvant treatment strategies should be tested in patients at substantial risk for disease progression and death. Neither the FIGO nor AJCC staging system is ideal for identifying such patients, suggesting a need for a uterine LMS-specific staging system to better target patients for trials of adjuvant therapies.